Diabetics across the nation can be heard cheering Sunday as the Food and Drug Administration passes an inhaled Insulin treatment, an alternative to the daily shot routine that millions have to do on a daily basis.

The panel voted by seven to two to recommend approving the product, called Exubera, on the grounds that its advantages in terms of ease of administration and its potential to improve patient compliance outweighed lingering doubts about its safety.

Exubera will not completely erase the shot routine but it will limit the amount a Diabetic would have to take. The medicine is a short-acting insulin delivered at mealtimes.